IP40
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well… Read more
IP40 (IP40) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.003x
Based on the latest financial reports, IP40 (IP40) has a cash flow conversion efficiency ratio of 0.003x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€22.00K) by net assets (€6.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
IP40 - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how IP40's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
IP40 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IP40 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Little Green Pharma Ltd
AU:LGP
|
0.003x |
|
PYRAMID TECHNOPLAST ORD (BSE)
NSE:PYRAMID
|
N/A |
|
Matahari Putra Prima Tbk
JK:MPPA
|
0.112x |
|
IGM BIOSCIENCES DL-01
F:1K0
|
N/A |
|
artnet AG Namens-Aktien o.N.
XETRA:ART
|
0.034x |
|
Akdeniz Yatirim Holding AS
IS:AKYHO
|
0.058x |
|
Bersama Zatta Jaya
JK:ZATA
|
0.033x |
|
Canfor Pulp Products Inc
PINK:CFPUF
|
-0.059x |
Annual Cash Flow Conversion Efficiency for IP40 (2021–2024)
The table below shows the annual cash flow conversion efficiency of IP40 from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €7.02 Million | €-1.58 Million | -0.225x | +74.74% |
| 2023-12-31 | €4.39 Million | €-3.90 Million | -0.890x | +8.67% |
| 2022-12-31 | €6.22 Million | €-6.07 Million | -0.975x | -32.48% |
| 2021-12-31 | €9.01 Million | €-6.63 Million | -0.736x | -- |